<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835168</url>
  </required_header>
  <id_info>
    <org_study_id>BT-11-EoE</org_study_id>
    <nct_id>NCT04835168</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Landos Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Landos Biopharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed Phase 1b study design is a randomized, placebo-controlled, double-blind, study&#xD;
      to evaluate the safety and pharmacokinetics of oral BT-11 in active eosinophilic esophagitis.&#xD;
&#xD;
      The primary and secondary objectives of this study is to establish safety and&#xD;
      pharmacokinetics of orodispersible BT-11 in active eosinophilic esophagitis (EoE).&#xD;
&#xD;
      The exploratory objectives of this study will include effects on disease activity measured by&#xD;
      symptoms, endoscopy, histology and biomarkers, health-related quality of life,&#xD;
      pharmacokinetics, and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 36 subjects with active eosinophilic esophagitis (≥ 15 eosinophils/HPF; SDI PRO ≥&#xD;
      5) will be randomized in a 1:1:1 ratio to receive BT-11 500 mg twice daily, BT-11 1000 mg&#xD;
      once daily, or placebo. Each of the treatment arms will comprise 12 subjects. The&#xD;
      randomization will be stratified by ongoing PPI use at baseline (yes/no) and prior&#xD;
      corticosteroid use (yes/no).&#xD;
&#xD;
      The study will consist of a 28-day screening period, a 12-week induction phase, and a 2-week&#xD;
      post-treatment safety follow-up period. A final analysis will be conducted after all subjects&#xD;
      have reached Week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>BT-11 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT-11 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT-11 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT-11 500mg</intervention_name>
    <description>Subjects will be randomized (1:1:1) to receive BT-11 1000 mg once daily, BT-11 500 mg twice daily, or placebo twice daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive tubes containing the study drug (BT-11 1000 mg, BT-11 500 mg, or placebo).</description>
    <arm_group_label>BT-11 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT-11 1000mg</intervention_name>
    <description>Subjects will be randomized (1:1:1) to receive BT-11 1000 mg once daily, BT-11 500 mg twice daily, or placebo twice daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive tubes containing the study drug (BT-11 1000 mg, BT-11 500 mg, or placebo).</description>
    <arm_group_label>BT-11 1000mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT-11 Placebo</intervention_name>
    <description>Subjects will be randomized (1:1:1) to receive BT-11 1000 mg once daily, BT-11 500 mg twice daily, or placebo twice daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive tubes containing the study drug (BT-11 1000 mg, BT-11 500 mg, or placebo).</description>
    <arm_group_label>BT-11 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male and female subjects aged 18 to 65 years with a diagnosis of eosinophilic&#xD;
             esophagitis for at least 3 months;&#xD;
&#xD;
          -  active eosinophilic esophagitis with ≥ 15 eosinophils/HPF in at least 2 of 3 biopsied&#xD;
             levels of the esophagus (distal, mid, or proximal), SDI PRO ≥ 5 and 2 or more episodes&#xD;
             of dysphagia per week on average; willing to adhere to a stable diet throughout the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any active or history of gastrointestinal conditions aside from eosinophilic&#xD;
             esophagitis including Crohn's disease, ulcerative colitis, celiac disease or&#xD;
             achalasia;&#xD;
&#xD;
          -  gross endoscopic abnormalities in the stomach or duodenum at baseline or found on&#xD;
             biopsy specimens;&#xD;
&#xD;
          -  impending or history of need for esophageal surgery;&#xD;
&#xD;
          -  esophageal strictures incapable of being passed by endoscope without dilation;&#xD;
&#xD;
          -  use of biologics, corticosteroids, or immunosuppressants within 4 weeks or 5&#xD;
             half-lives prior to baseline, whichever is longer;&#xD;
&#xD;
          -  recent bacterial, fungal or viral infection prior to screening or baseline;&#xD;
&#xD;
          -  presence or history of any medical condition, including cancer, that may influence the&#xD;
             results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti Chauhan</last_name>
    <role>Study Director</role>
    <affiliation>Landos Biopharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyoti Chauhan</last_name>
    <phone>5402182232</phone>
    <email>jyoti@landosbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josep Bassaganya-Riera</last_name>
    <email>jbr@landosbiopharma.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

